Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
IPO Year: 1996
Exchange: NASDAQ
Website: geron.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $1.50 | Sector Outperform → Sector Perform | Scotiabank |
| 2/27/2025 | $3.50 → $2.00 | Buy → Neutral | B. Riley Securities |
| 2/26/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | $8.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
| 4/29/2024 | $10.00 | Buy | TD Cowen |
| 3/15/2024 | $4.00 → $5.00 | Buy | Needham |
| 9/12/2023 | $4.00 | Neutral → Buy | Goldman |
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4/A - GERON CORP (0000886744) (Issuer)
8-K - GERON CORP (0000886744) (Filer)
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
10-Q - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
DEFA14A - GERON CORP (0000886744) (Filer)
DEF 14A - GERON CORP (0000886744) (Filer)
8-K/A - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level. "Gaurav brings extensive strategic leadership to Geron, and we believe his demonstrated track record in both corporate strategy and capital formation will add tremendous value as we look forward to a potential commercial launch in 2024
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms. Bloom's retirement brings to a close a remarkable career of nearly 30 years on Geron's finance team, including serving the last twelve years as CFO. "On behalf of the Board and our entire team, I would first like to express our deep appreciation and admiration for the countless contributions Olivia has made during her extraor
Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022. "With his three decades in the biopharmaceutical industry across business development and investment and corporate strategy, John is a highly respected and seasoned R&D executive with valuable pharmaceutical and biotechnology experience. We enthusiastically welcome him to the Board," said John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer. "We believe John's expertise will add commercial and strategic perspectives in guiding our objectives to advance imetelstat
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022. Dr. Feller will succeed Dr. Aleksandra Rizo, Geronʻs current Chief Medical Officer, who will transition to a consultant role to the Company, as Senior Medical and Regulatory Advisor. Outside of Geron, Dr. Rizo has accepted a leadership position with a privately held discovery and preclinical-stage platform biotechnology company. Dr. Feller has been instrumental in the design, execution and management of the imetelstat development program for the past seven years, starting when s
Geron Corporation (NASDAQ:GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. "Ed Koval's business development expertise, extensive industry network and successful track record in corporate deal-making further strengthens our executive team," said John A. Scarlett, M.D., Chairman and Chief Executive Officer. "With top-line results from our IMerge Phase 3 trial in lower risk MDS expected 13 months from now, and an interim analysis of our ongoing IMpactMF Phase 3 trial in refractory myelofibrosis expecte
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity